Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous belimumab in adults with connective tissue disease-associated interstitial lung disease
CTR20243677Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by GSK. Started Oct 2024; status: active.
02
Drugs
belimumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on CTR20243677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243677.